Lineage Cell Therapeutics (LCTX) to Release Earnings on Monday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is projected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $1.92 on Monday. The business has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.63. The company has a market capitalization of $442.23 million, a P/E ratio of -6.62 and a beta of 1.73. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $2.09.

Wall Street Analyst Weigh In

LCTX has been the subject of a number of research analyst reports. D. Boral Capital restated a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Monday, February 9th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, November 24th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Lineage Cell Therapeutics presently has an average rating of “Buy” and an average price target of $4.67.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of Lineage Cell Therapeutics by 1,578.9% during the first quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock valued at $237,000 after buying an additional 497,168 shares during the period. Rhumbline Advisers raised its holdings in Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after acquiring an additional 18,092 shares during the last quarter. XTX Topco Ltd lifted its stake in shares of Lineage Cell Therapeutics by 117.8% during the 2nd quarter. XTX Topco Ltd now owns 94,054 shares of the company’s stock worth $85,000 after purchasing an additional 50,876 shares during the period. Jump Financial LLC purchased a new position in shares of Lineage Cell Therapeutics during the 2nd quarter worth $28,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Lineage Cell Therapeutics during the second quarter worth $69,000. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.